|
Luzina E.V., Lazebnik L.B., Lareva N.V., Zhilina A.A., Moskvitina A.A.
Peculiarities of clinical manifestations of Helicobacter pylori infection in healthcare professionals
|
№5 / 2024
|
|
Gorelov A.V., Andreeva I.V., Zakharenko S.M., Sinopalnikov A.I.
The use of probiotics containing a combination of Lactobacillus acidophilus LA-5 and Bifidobacterium animalis subsp. lactis BB-12 strains: Meta-analysis of efficacy in the prevention of antibiotic-associated diarrhea and in Helicobacter pylori eradication therapy
|
№10 / 2023
|
|
Bakulina N.V., Savilova I.V., Lutaenko E.A., Tsurtsumia D.B.
Perspectives for the use of nanotechnologies in Helicobacter pylori eradication
|
№7 / 2023
|
|
Girfanova L.G., Khlynova O.V.
Cholesterosis of the gallblader and clinical and diagnostical characteristics of patients with different body weight
|
№7 / 2023
|
|
Luzina E.V., Tomina E.A., Zhigzhitova E.B., Lareva N.V.
Clinical manifestations of chronic atrophic gastritis: Guidelines, literature review and own observation
|
№2 / 2023
|
|
Vasilyeva L.V., Suslova E.Yu., Gosteva E.V.
Pathogenic factors of Helicobacter pylori in patients with coronary heart disease in combination with peptic ulcer
|
№4 (приложение) / 2022
|
|
Golubkina E.V., Levitan B.N., Umerova A.R., Kamneva N.V.
The effectiveness of standard triple anti-helicobacter first line therapy – the experience of the last decade
|
№4 / 2019
|
Русский
